OYST News and Press, Oyster Point Pharma Inc. From 05/15/20

PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its...

PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has commen...

Protalix Reports Positive Topline Results for Phase III Data Protalix BioTherapeutics Inc. ( PLX ) announced positive topline data from Phase III BRIDGE clinical trial of its lead drug candidate PRX-102. This Phase III study was an open label, single arm switch-over 12 month long study a...

Image source: The Motley Fool. Oyster Point Pharma, Inc.   (NASDAQ: OYST) Q1 2020 Earnings Call May 11, 2020 , 8:00 a.m. ET Operator Continue reading

Oyster Point Pharma Inc (OYST) Q1 2020 Earnings Conference Call May 11, 2020 8:00 AM ET Company Participants Daniel Lochner – Chief Financial Officer Jeffrey Nau – President and Chief Executive Officer John Snisarenko – Chief Commercial Officer Conference ...

Thinly traded Oyster Point Pharma ( OYST -8.7% ) is down on 30% higher volume, a modest 99K shares, in reaction to topline results from a Phase 3 clinical trial, ONSET-2 , evaluating lead candidate OC-01 (verenicline) nasal spray in patients with mild, moderate and severe dry eye diseas...

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with their 2020 Q1 earnings Read more ...

ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spray versus control (p<0.0001) Key secondary symptom endpoints also met in t...

Oyster Point Pharma (NASDAQ: OYST ): Q1 GAAP EPS of -$0.77 beats by $0.22 . More news on: Oyster Point Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128.6 million as of March 31, 2020 Conference Call and Webcast S...